{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:34:48Z","timestamp":1787614488685,"version":"build-2736575974"},"reference-count":41,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca"},{"name":"GSK"},{"name":"Teva Pharma S.L."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>A study was conducted in 98 adult patients diagnosed with severe eosinophilic asthma (73.5% women, mean age 47.2 years) and followed prospectively for 1 year. The aim of the study was to characterize this population and to identify factors associated with poor prognosis at 1 year of follow-up. At the initial visit, uncontrolled severe asthma was diagnosed in 87.7% of patients. Allergic sensitization was observed in 81.7% (polysensitization in 17.3%), with clinically significant allergic asthma in 45%. The mean percentage of sputum eosinophils was 4.7% (standard deviation(SD) 6.3%) and the mean (SD) blood eosinophil count 467 (225) cells\/\u00b5L. Almost half of the patients (48.3%) had sputum eosinophilia (&gt;3% eosinophils). Sputum eosinophils correlated significantly with peripheral eosinophilia (p = 0.004) and, to a lesser extent, with fractional exhaled nitric oxide (FeNO) (p = 0.04). After 1 year, 48 patients (49%) had uncontrolled asthma in all visits, and 50 (51%) had controlled asthma in some visits. Airway obstruction (FEV1 &lt; 80% predicted) was the main reason for uncontrolled asthma. In the multivariate analysis, an obstructive pattern (odds ratio (OR) 7.45, 95% confidence interval (CI) 2.41\u201323.03, p &lt; 0.0001) and the patient\u2019s age (OR 1.045, 95% CI 1.005\u20131.086, p = 0.026) were independent predictors of poor asthma control. In adult-onset and long-standing asthma, serum interleukin (IL) IL-17 was higher in the uncontrolled asthma group. This study contributes to characterizing patients with severe eosinophilic asthma in real-world clinical practice.<\/jats:p>","DOI":"10.3390\/jpm13071173","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:47:03Z","timestamp":1690159623000},"page":"1173","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characterization and Factors Associated with Poor Asthma Control in Adults with Severe Eosinophilic Asthma"],"prefix":"10.3390","volume":"13","author":[{"given":"Clara","family":"Padr\u00f3-Casas","sequence":"first","affiliation":[{"name":"Severe Asthma Unit, Allergy Section, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Basaga\u00f1a","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Allergy Section, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rivera-Ort\u00fan","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Department of Pneumology, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Universitat Aut\u00f2noma de Barcelona, Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Garc\u00eda-Oliv\u00e9","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Department of Pneumology, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Universitat Aut\u00f2noma de Barcelona, Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Pollan-Guisasola","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Department of Otorhinolaryngology, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Teniente-Serra","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Immunology Department, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mart\u00ednez-C\u00e1ceres","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Head of the Immunology Department, Department of Cell Biology, Physiology and Immunology, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Associate Professor of Immunology, Universitat Aut\u00f2noma de Barcelona, Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Tom\u00e1s","family":"Navarro","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia, Hospital Universitari Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Abad-Capa","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Department of Pneumology, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Universitat Aut\u00f2noma de Barcelona, Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Rosell","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Department of Pneumology, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Universitat Aut\u00f2noma de Barcelona, Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Roger","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Allergy Section, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00ednez-Rivera","sequence":"additional","affiliation":[{"name":"Severe Asthma Unit, Department of Pneumology, Hospital Universitari Germans Trias i Pujol, The Germans Trias i Pujol Research Institute (IGTP), Universitat Aut\u00f2noma de Barcelona, Carretera de Canyet s\/n, E-08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"key":"ref_1","unstructured":"Global Initiative for Asthma (2022, October 10). Global Strategy for Asthma Management and Prevention. Available online: https:\/\/www.ginaasthma.org."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0300-2896(15)32812-X","article-title":"Comit\u00e9 Ejecutivo de GEMA. GEMA4.0. Gu\u00eda espa\u00f1ola para el manejo del asma [PlGEMA(4.0). Guidelines for Asthma Management]","volume":"51","year":"2015","journal-title":"Arch. Bronconeumol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Domingo, C., Sicras-Mainar, A., Sicras-Navarro, A., Sogo, A., Mirapeix, R.M., and Engroba, C. (2022). Prevalence, T2-biomarkers and cost of severe asthma in the era of biologics: The BRAVO-1 study. J. Investig. Allergol. Clin. Immunol., Online ahead of print.","DOI":"10.2139\/ssrn.3972208"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 69, 89\u201395.","DOI":"10.1067\/mcp.2001.113989"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am. J. Res. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/02770903.2018.1534967","article-title":"The prevalence and disease burden of severe eosinophilic asthma in Japan","volume":"56","author":"Nagasaki","year":"2019","journal-title":"J. Asthma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1440-1843.2006.00784.x","article-title":"Inflammatory subtypes in asthma: Assessment and identification using induced sputum","volume":"11","author":"Simpson","year":"2006","journal-title":"Respirology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2015","journal-title":"Thorax"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: A post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2100413","DOI":"10.1183\/13993003.00413-2021","article-title":"Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma","volume":"58","author":"Kraft","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_13","first-page":"3s","article-title":"Sputum induction","volume":"37","author":"Paggiaro","year":"2002","journal-title":"Eur. Respir. J. Suppl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1089\/jamp.2015.1212","article-title":"Validation of the \u2018Test of the Adherence to Inhalers\u2019 (TAI) for Asthma and COPD Patients","volume":"29","author":"Plaza","year":"2016","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1378\/chest.115.5.1265","article-title":"Validation of a standardized version of the Asthma Quality of Life Questionnaire","volume":"115","author":"Juniper","year":"1999","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2045-7022-3-3","article-title":"The skin prick test\u2014European standards","volume":"3","author":"Heinzerling","year":"2013","journal-title":"Clin. Transl. Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1164\/ajrccm.154.2.8756799","article-title":"Indices of airway inflammation in induced sputum: Reproducibility and validity of cell and fluid-phase measurements","volume":"154","author":"Pizzichini","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_19","first-page":"1s","article-title":"Standardised methodology of sputum induction and processing","volume":"37","author":"Sterk","year":"2002","journal-title":"Eur. Respir. J. Suppl."},{"key":"ref_20","unstructured":"Belda, J., Giner, J., Torrej\u00f3n, M., and Casan, P. (2004). Manual SEPAR de Procedimientos, Publicaciones Permanyer."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2019.03.006","article-title":"Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study","volume":"151","author":"Callejas","year":"2019","journal-title":"Respir. Med."},{"key":"ref_22","first-page":"179","article-title":"Patients in the IDEAL cohort: A snapshot of severe asthma in France","volume":"36","author":"Pison","year":"2019","journal-title":"Rev. Mal. Respir."},{"key":"ref_23","first-page":"659","article-title":"The ARIETTA study: Baseline demographics in a real-world setting in patients with severe asthma","volume":"50","author":"Buhl","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaip.2013.11.013","article-title":"Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4\u20136 asthma therapy in the TENOR cohort","volume":"2","author":"Calhoun","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0140-6736(19)33005-3","article-title":"Intersection of biology and therapeutics: Type 2 targeted therapeutics for adult asthma","volume":"395","author":"Peters","year":"2020","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.rmed.2007.05.010","article-title":"Changing pattern of sputum cell counts during successive exacerbations of airway disease","volume":"101","author":"Cook","year":"2007","journal-title":"Respir. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1046\/j.1365-2222.2000.00919.x","article-title":"Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients","volume":"30","author":"Giannini","year":"2000","journal-title":"Clin. Exp. Allergy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.arbr.2015.12.012","article-title":"Variability in asthma inflammatory phenotype in induced sputum. Frequency and causes","volume":"52","author":"Crespo","year":"2016","journal-title":"Arch. Bronconeumol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MCP.0b013e32835b118e","article-title":"Induced sputum in asthma: Diagnostic and therapeutic implications","volume":"19","author":"Davies","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/thoraxjnl-2018-211540","article-title":"Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or Sputum eosinophils): A systematic review and meta-analysis","volume":"73","author":"Petsky","year":"2018","journal-title":"Thorax"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S2213-2600(15)00050-8","article-title":"Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: A systematic review and meta-analysis","volume":"3","author":"Korevaar","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-018-0248-7","article-title":"Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma","volume":"14","author":"Gao","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jaci.2009.02.034","article-title":"Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide\/formoterol","volume":"123","author":"Pavord","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaci.2010.05.032","article-title":"Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma","volume":"126","author":"Nair","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaci.2017.07.014","article-title":"Epidemiology and natural history of asthma: Outcomes and treatment regimens study group. More than a decade follow-up in patients with severe or difficult-to-treat asthma: The epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) II","volume":"141","author":"Chipps","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/JAA.S211246","article-title":"Prevalence and impact of risk factors for poor asthma outcomes in a large, specialist-managed patient cohort: A real-life study","volume":"12","author":"Tomisa","year":"2019","journal-title":"J. Asthma Allergy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chest.2019.10.009","article-title":"Recent advances in severe asthma: From phenotypes to personalized medicine","volume":"157","author":"Schoettler","year":"2020","journal-title":"Chest"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1248\/bpb.b19-00095","article-title":"Steroid-resistant asthma and neutrophils","volume":"43","author":"Nabe","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/all.13072","article-title":"Allergy in severe asthma","volume":"72","author":"Bakirtas","year":"2017","journal-title":"Allergy"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/7\/1173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:17:07Z","timestamp":1760127427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/7\/1173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jpm13071173"],"URL":"https:\/\/doi.org\/10.3390\/jpm13071173","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]}}}